Tumor Necrosis Factor Inhibitors

Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022.

PHILADELPHIA — Combination therapy with celecoxib plus golimumab failed to show significant superiority to golimumab alone in slowing spine damage in radiographic axial spondyloarthritis, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Patients who started TNF inhibitors earlier in their ankylosing spondyloarthritis disease course, vs. no initiation, have a higher risk for cardiovascular events, according to data presented at ACR Convergence 2022.

SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.

It is crucial that patients with juvenile arthritis stay active throughout their childhood for a better chance at building stronger bones, according to DMOS Orthopaedic Centers.

TNF inhibitor use in pregnant patients with well-controlled rheumatoid arthritis reduces the risk for children born small-for-gestational-age, according to data published in Annals of the Rheumatic Diseases.

Infections are more common in patients with rheumatoid arthritis who receive tofacitinib compared with those who receive TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

Although oncologists take the lead in cancer management with immunotherapies, rheumatologist input is essential to managing the ensuing immune-related adverse events, which pose challenges to coordinated patient care.

Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

A treat-to-target strategy in which TNF inhibitors are tapered is non-inferior to a regimen without tapering for maintaining low disease activity in patients with psoriatic arthritis or axial spondyloarthritis, according to data.